子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Selective estrogen receptor modulators containing a phenylsulfonyl group | US12100093 | 2008-04-09 | US07585977B2 | 2009-09-08 | Robert Dean Dally; Jeffrey Alan Dodge; Scott Alan Frank; Scott Alan Jones; Timothy Alan Shepherd; Owen Brendan Wallace; Kin Chlu Fong; Conrad Wilson Hummel; George Sal Lewis |
| The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata. | ||||||
| 82 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | US11273712 | 2005-11-14 | US07432268B2 | 2008-10-07 | Timothy Guzi; Kamil Paruch; Alan Mallams; Jocelyn D. Rivera; Ronald J. Doll; Viyyoor M. Girijavallabhan; Jonathan A. Pachter; Yi-Tsung Liu; Anil K. Saksena |
| There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases. | ||||||
| 83 | Novel m3 muscarinic acetylcholine receptor antagonists | US10581229 | 2004-12-03 | US20070179180A1 | 2007-08-02 | Jakob Busch-Petersen; Jian Jin; Michael Palovich; Wei Fu |
| Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | ||||||
| 84 | Organic dye used in dye-sensitized solar cell | US11236935 | 2005-09-27 | US20070073052A1 | 2007-03-29 | Marappan Velusamy; Koilpitchai Justin Thomas; Jiann Lin; Kuo-Chuan Ho; Ying-Chan Hsu |
| An organic dye used in a dye-sensitized solar cell is described, having general formula (1): D-Sp1-Ch-Sp2-Acc-Y (1)wherein the groups D, Ch, Acc and Y are conjugate with each other, the group D is a donor group, the group Ch is a chromophore rendering low HOMO-LUMO gap or a polyaromatic chromophore, the group Acc is an acceptor group, the group Y is an anchoring group, and each of Sp1 and Sp2 represents a single bond or a spacer group allowing conjugation between the groups D and Ch or between the groups Ch and Acc. | ||||||
| 85 | Pyrazine-2-carboxyamide derivatives | US11366007 | 2006-02-28 | US20060199828A1 | 2006-09-07 | Georg Jaeschke; Sabine Kolczewski; Richard Porter; Eric Vieira |
| The present invention is concerned with novel pyrazine 2-carboxyamide derivatives of formula (I) wherein R1, R2 and R3 are as defined in the specification. These compounds are useful for the treatment of CNS disorders. | ||||||
| 86 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | US11273712 | 2005-11-14 | US20060069103A1 | 2006-03-30 | Timothy Guzi; Kamil Paruch; Alan Mallams; Jocelyn Rivera; Ronald Doll; Viyyoor Girijavallabhan; Jonathan Pachter; Yi-Tsung Liu; Anil Saksena |
| There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases. | ||||||
| 87 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | US11045967 | 2005-01-28 | US20060014755A1 | 2006-01-19 | Timothy Guzi; Kamil Paruch; Alan Mallams; Jocelyn Rivera; Ronald Doll; Viyyoor Girijavallabhan; Jonathan Pachter; Yi-Tsung Liu; Anil Saksena |
| There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed: are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases. | ||||||
| 88 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | US10235627 | 2002-09-05 | US06903102B2 | 2005-06-07 | Timothy J. Guzi; Kamil Paruch; Alan K. Mallams; Jocelyn D. Rivera; Ronald J. Doll; Viyyoor M. Girijavallabhan; Jonathan A. Pachter; Yi-Tsung Liu; Anil K. Saksena |
| There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases. | ||||||
| 89 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | US10235627 | 2002-09-05 | US20040132736A1 | 2004-07-08 | Timothy J. Guzi; Kamil Paruch; Alan K. Mallams; Jocelyn D. Rivera; Ronald J. Doll; Viyyoor M. Girijavallabhan; Jonathan A. Pachter; Yi-Tsung Liu; Anil K. Saksena |
| There are disclosed compounds of the formula (I): 1 prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17 null-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases. | ||||||
| 90 | Tertiary amine salts of j | US2590632D | US2590632A | 1952-03-25 | ||
| 91 | SYNTHESIS OF PHOTOVOLTAIC CONJUGATED POLYMERS | PCT/US2013026092 | 2013-02-14 | WO2013123157A2 | 2013-08-22 | WANG SHUANGXI; SHI CHENJUN; CHEN RUBY; ZHANG JUNLIAN; HUANG HUI; WU YUE; WANG WEI; PALKAR AMIT; HE TING |
| A method of making a fluorothieno[3,4-b]thiophene derivatives and photovoltaic polymers containing same using 3-bromothiophene-2-carboxylic acid as a starting material. This synthetic route provides an easier synthesis as well as greater yield and a purer product, which produces superior results over the prior art less pure products. The resulting materials can be used in a variety of photovoltaic applications and devices, especially solar cells. | ||||||
| 92 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PCT/US2004040668 | 2004-12-03 | WO2005055941A3 | 2006-02-16 | BUSCH-PETERSEN JAKOB; JIN JIAN; MOORE MICHAEL LEE; RIVERO RALPH A; SHI DONGCHUAN; WANG FENG; WANG YONGHUI; FU WEI; PALOVICH MICHAEL R |
| Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | ||||||
| 93 | 11-BETA HSD1 INHIBITORS | PCT/US2007003134 | 2007-02-07 | WO2007092435A3 | 2007-12-27 | XIANG JASON SHAOYUN; SAIAH EDDINE; TAM STEVE Y; MCKEW JOHN C; CHEN LIHREN; IPEK MANUS; LEE KATHERINE; LI HUAN-QUI; LI JIANCHANG; LI WEI; MANSOUR TAREK SUHAYL; SURI VIPIN; VARGAS RICHARD; WU YUCHUAN; WAN ZHAO-KUI; LEE JINBO; BINNUN EVA; WILSON DOUGLAS P |
| This invention relates to inhibiting 11ßHSD1. | ||||||
| 94 | エストロゲン受容体モジュレーター及びその使用 | JP2017533026 | 2015-12-17 | JP2018504384A | 2018-02-15 | スミス, ニコラス ディー.; リャン, ジュン; オートワイン, ダニエル フレッド; ワン, シャオチン; カフラマン, マーメット; ナガサワ, ジョニー ワイ.; グッドエーカー, サイモン チャールズ; レイ, ニコラス チャールズ; ゴヴェク, スティーヴン ピー. |
| 本明細書に記載されているのは、式(I)のエストロゲン受容体モジュレーターである化合物、及びその立体異性体、互変異性体又は薬学的に許容される塩であり、式中、SERMFは、本明細書に記載されている置換基及び構造的特色を有する選択的エストロゲン受容体モジュレーター断片である。記載されているのはまた、本明細書に記載されている化合物が含まれる薬学的組成物及び医薬、並びにエストロゲン受容体媒介性又は依存性である疾患又は状態を治療するためにこうしたエストロゲン受容体モジュレーターを単独でも他の化合物と組み合わせても使用する方法である。【選択図】なし | ||||||
| 95 | 拡張型心筋症（ＤＣＭ）の処置のための４−メチルスルホニル置換ピペリジンウレア化合物 | JP2017538593 | 2016-01-21 | JP2018502883A | 2018-02-01 | ジョハン・オスロブ; ダニエル・オーベル; ジェイ・キム; ロバート・マクドウェル; ヨンホン・ソン; アーヴィンダー・シュラン; ミン・ヂョン |
| 本発明は、拡張型心筋症(DCM)、および左心室および/または右心室収縮機能障害または収縮予備量に関連する状態を処置するために有用な、新規4−メチルスルホン置換ピペリジンウレア化合物を提供する。化合物の合成および物性評価、ならびにDCMおよび心臓疾患の他の形態を処置する方法が記載されている。 | ||||||
| 96 | 有機電界発光化合物、ならびにこれを含む有機電界発光材料及び有機電界発光デバイス | JP2017513089 | 2015-09-25 | JP2017531621A | 2017-10-26 | ドゥ−ヒョン・ムン; ジョン−ウン・ヤン; ヒー−リョン・カン; ヨン−ムク・リム; ジ−ソン・ジュン; ヒ−チュン・アン; ジン−リ・ホン; ス−ヒュン・リー; ビトナリ・キム; テ−ジン・リー |
| 本開示は、有機電界発光化合物、ならびにこれを含む有機電界発光材料及び有機電界発光デバイスに関する。本開示の有機電界発光化合物は、優れた色純度、溶解性、及び熱安定性を有する。本開示の有機電界発光化合物及び有機電界発光材料を含むことによって、低駆動電圧、優れた電流及び電力効率、ならびに著しく改善された寿命を示す有機電界発光デバイスが提供され得る。【選択図】なし | ||||||
| 97 | パターン形成方法、及び電子デバイスの製造方法 | JP2013017949 | 2013-01-31 | JP6031369B2 | 2016-11-24 | 山口 修平; 冨賀 敬充; 吉野 文博; 古谷 創; 白川 三千紘; 藤田 光宏 |
| 98 | CNS疾患の処置のためのアリールスルホンアミド | JP2013528677 | 2011-09-16 | JP5899218B2 | 2016-04-06 | コワツコヴスキー,マルチン; コヴァルスキー,ピオトル; ヤスコヴスカ,ヨランタ; マルチンコヴスカ,モニカ; ミトゥカ,カタルジナ; ブッキ,アダム; ヴェソウォヴスカ,アンナ; パヴウォウスキー,マチエユ |
| 99 | 感活性光線性または感放射線性樹脂組成物およびこれを用いたパターン形成方法 | JP2010150181 | 2010-06-30 | JP5645510B2 | 2014-12-24 | 修平 山口; 渋谷 明規; 明規 渋谷 |
| 100 | Aryl sulfonamides for the treatment of disease Cns | JP2013528677 | 2011-09-16 | JP2013540738A | 2013-11-07 | コワツコヴスキー，マルチン; コヴァルスキー，ピオトル; ヤスコヴスカ，ヨランタ; マルチンコヴスカ，モニカ; ミトゥカ，カタルジナ; ブッキ，アダム; ヴェソウォヴスカ，アンナ; パヴウォウスキー，マチエユ |
| Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system. | ||||||
QQ群二维码
意见反馈
意见反馈